References of "European Journal of Nuclear Medicine and Molecular Imaging"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEffect of diazepam on the efficacy of dual-phase FDG PET imaging.
Zhuang, Hongming; Hustinx, Roland ULg; Alavi, Abass

in European Journal of Nuclear Medicine and Molecular Imaging (2006), 33(2), 228-9230

Detailed reference viewed: 24 (2 ULg)
Peer Reviewed
See detailIodide organification disorder in autonomous thyroid nodule.
Tang, B.; Corvilain, B.; Seret, Alain ULg et al

in European Journal of Nuclear Medicine and Molecular Imaging (2006), 33(S2), 351

Detailed reference viewed: 29 (1 ULg)
Peer Reviewed
See detailComparison of noise, hot and cold contrast of eight tomographic camera models.
Seret, Alain ULg; Nguyen, Thibaut

in European Journal of Nuclear Medicine and Molecular Imaging (2006), 33(S2), 282

Detailed reference viewed: 25 (1 ULg)
Peer Reviewed
See detailImpact of the attenuation and scatter correction methods on hot and cold contrasts obtained with the Philips Gemini PET-scanner.
Seret, Alain ULg; Nguyen, T.; Bernard, Claire ULg

in European Journal of Nuclear Medicine and Molecular Imaging (2006), 33(S2), 316

Detailed reference viewed: 23 (5 ULg)
Peer Reviewed
See detailImprovement of parathyroid lesion visualization in primary hyperparathyroidism with 99mTc-MIBI pinhole SPECT: comparison with conventional SPECT and planar scintigraphy.
Ansquer, C.; Mirallié, E.; Oudoux, A. et al

in European Journal of Nuclear Medicine and Molecular Imaging (2006), 33(S2), 100

Detailed reference viewed: 15 (2 ULg)
Peer Reviewed
See detailClinical evaluation of iterative versus analytic reconstruction for parathyroid lesions visualization in primary hyperparathyroidism with 99mTc-MIBI pinhole SPECT.
Ansquer, C.; Mirallié, E.; Oudoux, A. et al

in European Journal of Nuclear Medicine and Molecular Imaging (2006), 33(S2), 355

Detailed reference viewed: 28 (2 ULg)
Peer Reviewed
See detailComparison of the current techniques used for the denoising of scintigraphic images
Kirkove, Murielle ULg; Seret, Alain ULg

in European Journal of Nuclear Medicine and Molecular Imaging (2006), 33(S2), 318

Detailed reference viewed: 26 (9 ULg)
Full Text
Peer Reviewed
See detailF-18-FDG PET in children with lymphomas
Depas, Gisèle ULg; De Barsy, Caroline; Jerusalem, Guy ULg et al

in European Journal of Nuclear Medicine and Molecular Imaging (2005), 32(1), 31-38

Purpose: The aim of this study was to retrospectively evaluate the performance of positron emission tomography (PET) with F-18-fluorodeoxyglucose (F-18-FDG) in children with lymphomas, at various stages ... [more ▼]

Purpose: The aim of this study was to retrospectively evaluate the performance of positron emission tomography (PET) with F-18-fluorodeoxyglucose (F-18-FDG) in children with lymphomas, at various stages of their disease. Methods: Twenty-eight children (mean age 12.5 years, 14 girls, 14 boys) with Hodgkin's disease (HD, n=17) or non-Hodgkin's lymphoma (NHL, n= 11) were evaluated. Patients were investigated at initial staging (n=19), early in the course of treatment (n=19), at the end of treatment (n=16) and during long-term follow-up (n=19). A total of 113 whole-body PET studies were performed on dedicated scanners. PET results were compared with the results of conventional methods (CMs) such as physical examination, laboratory studies, chest X-rays, computed tomography, magnetic resonance imaging, ultrasonography and bone scan when available. Results: At initial evaluation (group 1), PET changed the disease stage and treatment in 10.5% of the cases. In early evaluation of the response to treatment (group 2), PET failed to predict two relapses and one incomplete response to treatment. In this group, however, PET did not show any false positive results. There were only 4/75 false positive results for PET among patients studied at the end of treatment (group 3, specificity 94%) or during the systematic follow-up (group 4, specificity 95%), as compared with 27/75 for CMs (specificity 54% and 66%, respectively). Conclusion: F-18-FDG-PET is a useful tool for evaluating children with lymphomas. Large prospective studies are needed to appreciate its real impact on patient management. [less ▲]

Detailed reference viewed: 41 (5 ULg)
Peer Reviewed
See detailPerformances in hot and cold contrast of 32 camera heads assessed from planar views of the Picker's thyroid phantom.
Seret, Alain ULg

in European Journal of Nuclear Medicine and Molecular Imaging (2005), 32

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailFluorinated tracers for imaging cancer with positron emission tomography
Couturier, Olivier; Luxen, André ULg; Chatal, Jean-François et al

in European Journal of Nuclear Medicine and Molecular Imaging (2004), 31(8), 1182-1206

2-[F-18]fluoro-2-deoxy-D-glucose (FDG) is currently the only fluorinated tracer used in routine clinical positron emission tomography (PET). Fluorine-18 is considered the ideal radioisotope for PET ... [more ▼]

2-[F-18]fluoro-2-deoxy-D-glucose (FDG) is currently the only fluorinated tracer used in routine clinical positron emission tomography (PET). Fluorine-18 is considered the ideal radioisotope for PET imaging owing to the low positron energy (0.64 MeV), which not only limits the dose rate to the patient but also results in a relatively short range of emission in tissue, thereby providing high-resolution images. Further, the 110-min physical half-life allows for high-yield radiosynthesis, transport from the production site to the imaging site and imaging protocols that may span hours, which permits dynamic studies and assessment of potentially fairly slow metabolic processes. The synthesis of fluorinated tracers as an alternative to FDG was initially tested using nucleophilic fluorination of the molecule, as performed when radiolabelling with iodine-124 or bromide-76. However, in addition to being long, with multiple steps, this procedure is not recommended for bioactive molecules containing reactive groups such as amine or thiol groups. Radiochemical yields are also often low. More recently, radiosynthesis from prosthetic group precursors, which allows easier radiolabelling of biomolecules, has led to the development of numerous fluorinated tracers. Given the wide availability of 18F, such tracers may well develop into important routine tracers. This article is a review of the literature concerning fluorinated radiotracers recently developed and under investigation for possible PET imaging in cancer patients. Two groups can be distinguished. The first includes "generalist" tracers, i.e. tracers amenable to use in a wide variety of tumours and indications, very similar in this respect to FDG. These are tracers for non-specific cell metabolism, such as protein synthesis, amino acid transport, nucleic acid synthesis or membrane component synthesis. The second group consists of "specific" tracers for receptor expression (i.e. oestrogens or somatostatin), cell hypoxia or bone metabolism. [less ▲]

Detailed reference viewed: 25 (2 ULg)
Peer Reviewed
See detailSet-up of a camera quality programme in six departments: the initial experience
Seret, Alain ULg

in European Journal of Nuclear Medicine and Molecular Imaging (2004), 31

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailBody contour 180 degrees pinhole SPET with or without tilted detector: a phantom study
Seret, Alain ULg; Flérès, David; Firket, Olivier et al

in European Journal of Nuclear Medicine and Molecular Imaging (2003), 30(9), 1205-1210

This study investigated the feasibility of ordered subsets expectation maximisation (OS-EM) reconstruction of 180 degrees pinhole single-photon emission tomography (SPET) acquired in body contour mode ... [more ▼]

This study investigated the feasibility of ordered subsets expectation maximisation (OS-EM) reconstruction of 180 degrees pinhole single-photon emission tomography (SPET) acquired in body contour mode (variable distance between the detector and the axis of rotation for each projection) with or without a tilted detector head. Four non-circular orbits were designed bearing in mind the rotation radius and tilt angle values of previous pinhole SPET acquisitions in patients with circular orbits. The reconstructions were performed using a dedicated OS-EM algorithm. Reconstructed images of line and uniformity phantoms showed that the spatial and uniformity characteristics of the radioactive objects were preserved. In comparison with the circular orbits, the non-circular orbits allowed only a moderate gain (maximum 10%) in resolution. However, body contour pinhole SPET would significantly facilitate the camera set-up and in this way should decrease the camera set-up time, which is an important parameter in patient studies. [less ▲]

Detailed reference viewed: 52 (2 ULg)
Full Text
Peer Reviewed
See detailImaging of large vessel vasculitis with (18)FDG PET: illusion or reality? A critical review of the literature data
Belhocine, Tarik; Blockmans, Daniel; Hustinx, Roland ULg et al

in European Journal of Nuclear Medicine and Molecular Imaging (2003), 30(9), 1305-1313

Fluorine-18 fluorodeoxyglucose positron emission tomography ((18)FDG PET) plays a major role in the management of oncology patients. Owing to the singular properties of the glucose tracer, many patients ... [more ▼]

Fluorine-18 fluorodeoxyglucose positron emission tomography ((18)FDG PET) plays a major role in the management of oncology patients. Owing to the singular properties of the glucose tracer, many patients suffering from non-malignant diseases such as inflammatory or infectious diseases may also derive clinical benefit from the appropriate use of metabolic imaging. Large vessel vasculitides such as giant cell arteritis and Takayasu arteritis are other examples that may potentially extend the field of (18)FDG PET indications. The purpose of the present article is to assess the feasibility of metabolic imaging in vasculitis on the basis of the current literature data. In particular, the clinical context and the (18)FDG imaging patterns seen in patients with large vessel vasculitis are analysed in order to identify potential indications for metabolic imaging. [less ▲]

Detailed reference viewed: 35 (1 ULg)
Full Text
Peer Reviewed
See detailAdded value of whole body 18FDG PET imaging in monitoring uterine cancers.
BELHOCINE, T.; THILLE, A.; DE BARSY, C. et al

in European Journal of Nuclear Medicine and Molecular Imaging (2003), 30(SUPPL 2), 269

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailValue of 18FDG gamma camera coincidence imaging in the follow-up of head and neck squamous cell carcinoma.
PAQUET, N.; LEFEBVRE, B.; HUSTINX, Roland ULg et al

in European Journal of Nuclear Medicine and Molecular Imaging (2003), 30(SUPPL 2), 278

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailIntra-patient variability of SUV in normal tissues.
PAQUET, N.; HUSTINX, Roland ULg; FOIDART-WILLEMS, Jacqueline ULg

in European Journal of Nuclear Medicine and Molecular Imaging (2003), 30(SUPPL 2), 327

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailUsefulness of F-18-FDG PET in the post-therapy surveillance of endometrial carcinoma
Belhocine, Tarik; De Barsy, Caroline; Hustinx, Roland ULg et al

in European Journal of Nuclear Medicine and Molecular Imaging (2002), 29(9), 1132-1139

The aim of this study was to assess the usefulness of fluorine-18 tluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) in the post-therapy surveillance of endometrial carcinomas. Forty-one ... [more ▼]

The aim of this study was to assess the usefulness of fluorine-18 tluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) in the post-therapy surveillance of endometrial carcinomas. Forty-one fully corrected whole-body PET studies were performed in 34 women with previously treated endometrial cancers as a part of their follow-up programme. In 28 studies, FDG PET was indicated to localise a recurrence suspected at the control visits on the basis of clinical examination and/or radiological abnormalities (chest X-ray, CT or MRI) and/or elevated tumour marker levels (CA125, CEA). Another 13 studies were performed as a simple surveillance procedure. Overall, in 26 studies PET detected recurrent disease, which was confirmed either by histology (n=7) or by clinical and radiological outcomes (n=19). In 88% of the cases, the PET findings confirmed recurrence suggested by routine follow-up. In the remaining 12% of cases, PET detected asymptomatic recurrences that were unsuspected at the control visits. Whole-body PET accurately localised the site of confirmed recurrences as being above and below the diaphragm in 50%, only below the diaphragm in 35% and only above the diaphragm in 15%. In one patient, however, PET missed microscopic lung metastases shown on thoracic CT, and in three studies, metabolic imaging results were not confirmed. In I I of 12 negative PET studies, no subsequent clinical or radiological recurrences were observed with a median follow-up of 10 months. Overall, the results of PET agreed well with the final diagnosis (Cohen's kappa coefficient =0.78). In 9/26 patients (35%) with confirmed recurrences, the PET findings significantly altered the treatment choice by detecting either clinically or radiologically unsuspected distant metastases. The sensitivity, specificity, diagnostic accuracy and positive and negative predictive values of FDG PET imaging in the post-therapy surveillance of endometrial carcinomas were 96%, 78%, 90%, 89% and 91 %, respectively. Indeed, the high likelihood ratio for a positive test result (4.5) and the low likelihood ratio for a negative test result (0.05) demonstrated the clinical utility of metabolic imaging in "ruling in" disease as well as "ruling out" recurrence. In conclusion, whole-body FDG PET appears useful in the post-therapy surveillance of endometrial cancers, both for the accurate localisation of suspected recurrences and for the detection of asymptomatic recurrent disease. [less ▲]

Detailed reference viewed: 24 (0 ULg)
Full Text
Peer Reviewed
See detailThe potential of the beta-Microprobe, an intracerebral radiosensitive probe, to monitor the [(18)F]MPPF binding in the rat dorsal raphe nucleus.
Zimmer, L.; Pain, F.; Mauger, G. et al

in European Journal of Nuclear Medicine and Molecular Imaging (2002), 29(9), 1237-47

The aim of this study was to demonstrate the ability of a recently developed beta(+)-range sensitive intracerebral probe (beta-Microprobe) to measure the binding kinetics of [(18)F]MPPF, a well-documented ... [more ▼]

The aim of this study was to demonstrate the ability of a recently developed beta(+)-range sensitive intracerebral probe (beta-Microprobe) to measure the binding kinetics of [(18)F]MPPF, a well-documented 5-HT(1A) serotoninergic receptor ligand, in the dorsal raphe nucleus (DRN) of the anaesthetised rat. This midbrain nucleus presents a high concentration of 5-HT(1A) receptors known to be implicated in the effects of antidepressants. The difficulty confronting this study lay in the fact that the dimensions of the DRN are smaller than the detection volume of the beta-Microprobe. In the first part of the study, we studied the feasibility of this measurement from a theoretical point of view by autoradiography and a Monte Carlo simulation. We determined the optimal beta-Microprobe location close to the DRN and verified that this configuration allowed accurate determination of [(18)F]MPPF specific binding in the nucleus. In the second part of our study, we measured the in vivo time-concentration curves of [(18)F]MPPF binding in the DRN in comparison with the cerebellum. The specificity of [(18)F]MPPF binding in the DRN was confirmed by its displacement after non-labelled 5-HT(1A)antagonist injection (MPPF or WAY-100635). Moreover, we verified the feasibility of using beta-Microprobe monitoring and simultaneous validation by microdialysis to study the effect of an increase in extracellular serotonin, induced by fenfluramine injection, on [(18)F]MPPF binding in the DRN. Our theoretical simulations, confirmed by our experimental results, demonstrate the ability of this new device to monitor in vivo the binding of [(18)F]MPPF in the DRN of anaesthetised rodents. [less ▲]

Detailed reference viewed: 37 (7 ULg)